Ondansetron Use During Pregnancy: Birth Defects and Obstetric Outcomes.


Journal

Clinical nursing research
ISSN: 1552-3799
Titre abrégé: Clin Nurs Res
Pays: United States
ID NLM: 9208508

Informations de publication

Date de publication:
05 2023
Historique:
medline: 24 4 2023
pubmed: 14 3 2023
entrez: 13 3 2023
Statut: ppublish

Résumé

Ondansetron is a widely administered medication for nausea and vomiting of pregnancy. Further examination of its teratogenic capacity is necessary. This study examines the association between ondansetron treatment during pregnancy and birth defects and adverse obstetric outcomes. Patient data were extracted from Clalit Health Services, Israel. A propensity-score analysis was performed matching those exposed to ondansetron with those who were not. Findings identified 774 women exposed to ondansetron, matched 1:1 with unexposed control patients. No significant differences were found between the groups for: cleft palate, cardiovascular congenital abnormalities, spina bifida occulta, preterm delivery, or small for gestational age. Ondansetron may be a useful and safe alternative as treatment for women who suffer from hyperemesis gravidarum and do not respond to other antiemetic drugs. Notwithstanding, additional prospectively designed research is needed to establish the safety of ondansetron treatment during pregnancy.

Identifiants

pubmed: 36912091
doi: 10.1177/10547738231159062
doi:

Substances chimiques

Ondansetron 4AF302ESOS
Antiemetics 0

Types de publication

Journal Article

Langues

eng

Pagination

705-711

Auteurs

Sabaa Masarwe (S)

Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Rachel Shvartsur (R)

Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Eran Hadar (E)

Helen Schneider Hospital for Women, Rabin Medical Center, Petach-Tikva; and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Batya Betesh-Abay (B)

Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Neonatal Intensive Care, Soroka University Medical Center, Beer-Sheva, Israel.

Noam Peleg (N)

The Division of Gastroenterology, Rabin Medical Center, Sackler school of Medicine, Tel Aviv University, Tel Aviv, Israel.

Abed N Azab (AN)

Department of Nursing, School for Community Health Professions, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH